MarketVue® Report
Netherton Syndrome (U.S.), 2022

Syndicated market assessment report driven by primary market research

REPORT STORE

Netherton Syndrome (U.S.), October 2022

DOWNLOAD SAMPLE REPORT
DOWNLOAD REPORT BROCHURE
The MarketVue®: Netherton’s Syndrome market landscape report combines primary (KOL interviews) and secondary market research to empower strategic decision-making and provide a complete view of the market.
 
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
 
Topics covered in this report:
  • Disease overview: Review the disease pathophysiology and potential druggable targets
  • Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
  • Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
  • Unmet needs: Identify opportunities to address treatment or disease management gaps
  • Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
  • Value and access: Gain insights into the drug pricing landscape and payer controls within the disease market or analogous markets
 
Methodology:
Research for the MarketVue®: Netherton’s Syndrome report is supported by 8 qualitative interviews with key opinion leaders and secondary research.
 
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
 
Key companies mentioned:
  • Quoin Pharmaceuticals
  • Lifemax Laboratories
  • Sixera Pharma
  • Daiichi Sankyo
 
Key drugs mentioned:
  • Triamcinolone
  • Calcineurin
  • Ustekinumab (Stelara)
  • Secukinumab (Cosentyx)
  • QRX003
  • Dupilumab (Dupixent)
  • LM-030
  • SXR1096
  • DS-2325a
1. DISEASE OVERVIEW
A rare, inherited disorder of the skin characterized by scaling skin, bamboo hair, and increased susceptibility to infection
Figure 1.1. Clinical presentation of NS and related targets
NS falls under the category of autosomal recessive congenital ichthyoses
Figure 1.2. Classification of NS
Table 1.1. Severity of NS is typically dependent on body involvement though severity assessments exist
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. G6 diagnosed prevalent cases of NS by region
Table 2.1 Diagnosed prevalent and drug-treated patients in the G6
3. DIAGNOSIS AND CURRENT TREATMENT
Diagnosis overview
Figure 3.1. Diagnostic work-up for NS patients
Physician insights on diagnosis of NS
Treatment of NS
Treatment overview
Figure 3.2. Treatment goals for NS
Treatment flow for NS
Figure 3.3. Treatment algorithm for NS
Upsides and downsides of current NS treatment options
Physician perspectives on off-label biologics
Figure 3.4. Reservations around off-label biologic use in NS
Key treatment dynamics that shape disease management in NS
Figure 3.5 . Must-know NS treatment dynamics for now and the future
4. UNMET NEED
Overview
Figure 4.1. Physician-reported top unmet needs in NS patients
Other unmet needs for NS
5. PIPELINE ANALYSIS
Overview
Table 5.1. Emerging NS therapies, phase 1 to phase 3
The promising future of disease-modifying biologics
Figure 5.1. Advantages of a disease-modifying biologic in NS
6. VALUE & ACCESS
Overview
Figure 6.1. Reimbursement and access considerations for emerging therapies in NS
Table 6.1. Current therapy pricing, U.S. 2021-2022
Biologics face a rigorous approval process on commercial insurance plans
Dupixent for the use of atopic dermatitis and eosinophilic esophagitis as an analogue for potential NS therapies
Figure 6.2. Commercial insurance restrictions on Dupixent’s use in AD and EoE
7. METHODOLOGY
Primary market research approach
Epidemiology methodology
What is the difference between purchasing a published report and requesting a new report?

Published reports have been pre-produced on the specified date and can be delivered immediately. If you prefer to refresh an existing report or request an entirely new disease, REACH can create and deliver any new report within 15 business days.

How does REACH produce new primary market research reports in 15 business days?

By deploying our senior team to each of our reports, we can begin insight generation on day 1. The REACH team also recruits Key Opinion Leaders from our internal panel rather than outsourcing recruitment which enables us to quickly begin primary market research interviews.

Who writes REACH reports?

Each REACH report is produced by one of our senior US-based team members with 10+ years of experience in life sciences market research. We are deeply committed to ensuring REACH reports are high quality and strategic to enable informed decision-making for our clients.

Does REACH cover both rare and non-rare diseases?

REACH specializes in covering diseases and subpopulations that are not addressed by traditional market research reports. As such, we focus on rare diseases and niche subpopulations of more common conditions (e.g., Dupixent-refractory atopic dermatitis). Our flexible model enables in-depth assessments across all disease types, allowing us to support research for non-rare conditions as well.

Can I meet with the team to discuss the report?

Contact us to set up a call directly with the analyst who has written the report to answer any questions and discuss the key takeaways.

Published Report

Download immediately.


New Report

Updated upon purchase. Delivered in 15 days.


Undecided about purchasing this report?

» Inquire before buying

Reach out to learn more about report bundle discounts

Reach out to our team to learn more about our capabilities and view sample reports.

Contact us